Galderma Group

Galderma Group ROE

The Return on Equity (ROE) of Galderma Group (GALD.SW) as of Nov 6, 2026 is 7.88 %. In the previous year, Return on Equity (ROE) was 3.27 % — a change of 141.32% (higher).

ROE

7.88 %

YoY

141.32%

Last updated:

In 2025, Galderma Group's return on equity (ROE) was 7.88 %, a 141.32% increase from the 3.27 % ROE in the previous year.

The Galderma Group ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2021
-3.40 USD
Jan 1, 2022
-2.28 USD
Jan 1, 2023
-1.07 USD
Jan 1, 2024
3.27 USD
Jan 1, 2025
7.88 USD
The Galderma Group ROE history
YEARROEYoY
7.88 %+141.32%
3.27 %-406.49%
-1.07 %-53.18%
-2.28 %-33.15%
-3.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Galderma Group Stock analysis

What does Galderma Group do? Galderma Group AG, headquartered in Switzerland, operates in the healthcare sector, specializing in dermatological treatments and skincare solutions. The company serves global markets with a focus on innovative products for skin health. Listed on the stock exchange in March 2024, Galderma continues to expand its presence in the international healthcare industry. Galderma Group is one of the most popular companies on Eulerpool.

ROE Details

Decoding Galderma Group's Return on Equity (ROE)

Galderma Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Galderma Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Galderma Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Galderma Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Galderma Group stock

Return on Equity (ROE) of Galderma Group is 7.88 % in 2025.

Return on Equity (ROE) of Galderma Group changed from 3.27 % to 7.88 %, representing a 141.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Galderma Group since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Galderma Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Galderma Group

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Galderma Group